What’s Next for Axogen Inc (NASDAQ:AXGN) After Having Less Shares Shorted?

March 18, 2018 - By Peter Erickson

 What's Next for Axogen Inc (NASDAQ:AXGN) After Having Less Shares Shorted?

The stock of Axogen Inc (NASDAQ:AXGN) registered a decrease of 16.76% in short interest. AXGN’s total short interest was 945,600 shares in March as published by FINRA. Its down 16.76% from 1.14M shares, reported previously. With 213,500 shares average volume, it will take short sellers 4 days to cover their AXGN’s short positions. The short interest to Axogen Inc’s float is 3.54%.

The stock increased 1.48% or $0.55 during the last trading session, reaching $37.65. About 950,897 shares traded or 210.48% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since March 18, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.30 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 21 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Leerink Swann on Thursday, November 2. The stock has “Outperform” rating by Wedbush on Monday, November 7. Lake Street maintained AxoGen, Inc. (NASDAQ:AXGN) on Friday, March 2 with “Buy” rating. The firm has “Outperform” rating by Leerink Swann given on Tuesday, November 21. Cantor Fitzgerald maintained the shares of AXGN in report on Wednesday, February 28 with “Buy” rating. The firm earned “Buy” rating on Monday, September 11 by Roth Capital. The firm earned “Hold” rating on Tuesday, August 11 by Zacks. The rating was maintained by Wedbush with “Buy” on Tuesday, November 21. The stock has “Buy” rating by Cantor Fitzgerald on Monday, January 8. Wedbush maintained it with “Outperform” rating and $5 target in Friday, August 28 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.